- Home
- MNOV vs TCRX Comparison
MNOV vs TCRX Comparison
Compare MNOV & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | TCRX |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.5M | 64.1M |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MNOV | TCRX |
|---|---|---|
| Price | $1.53 | $0.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $7.00 | ★ $8.50 |
| AVG Volume (30 Days) | 103.8K | ★ 821.2K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $257,917.00 | ★ $8,423,000.00 |
| Revenue This Year | N/A | $286.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.13 | $0.91 |
| 52 Week High | $2.24 | $3.43 |
Technical Indicators
Market Signals| Indicator | MNOV | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.22 | 38.46 |
| Support Level | $1.48 | $0.99 |
| Resistance Level | $1.60 | $1.09 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 60.53 | 25.00 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.